The Latest in AML

FDA grants orphan designation to DHODH inhibitor for AML

August 21, 2018

AML

FDA puts partial hold on trial of vascular agent for AML, MDS

August 20, 2018

AML

Autotransplant is linked to higher AML, MDS risk

August 10, 2018

Vadastuximab talirine gives big boost to AML remission

August 2, 2018

AML

FDA approves Nivestym, second biosimilar to Neupogen

July 20, 2018

FDA approves IDH1 inhibitor for relapsed/refractory AML

July 20, 2018

AML

Genentech submits sNDA for venetoclax in untreated AML

July 12, 2018

Oral arsenic/ATRA is noninferior to IV form in APML

July 10, 2018

AML

Mutations may be detectable years before AML diagnosis

July 10, 2018

AML

Venetoclax with 5+2 chemo looks effective in older AML patients

July 9, 2018

AML

Q&A: Clinical implications of clonal hematopoiesis

June 22, 2018

AML

Dual-targeting CAR T active against AML in mice and one man

June 20, 2018

AML

Ivosidenib leads to complete responses in 32% of IDH1-mutated relapsed/refractory AML

June 3, 2018

AML

Under his IDH2: Epigenetic drivers of clonal hematopoiesis

May 31, 2018

AML

FDA to review FLT3 agent for refractory AML

May 29, 2018

AML